Spectral Diagnostics (OTCMKTS:EDTXF) Announces Earnings Results, Hits Expectations

Spectral Diagnostics (OTCMKTS:EDTXF) posted its earnings results on Friday. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01), Zacks reports. The business had revenue of $0.64 million for the quarter, compared to analyst estimates of $0.54 million.

Spectral Diagnostics Stock Performance

EDTXF traded up $0.01 on Friday, reaching $1.03. 13,337 shares of the company’s stock were exchanged, compared to its average volume of 7,337. Spectral Diagnostics has a twelve month low of $0.58 and a twelve month high of $1.31. The company’s 50 day moving average is $0.99 and its 200-day moving average is $0.99. The company has a market cap of $301.64 million, a price-to-earnings ratio of -8.57 and a beta of 0.09.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.